Milestone Pharmaceuticals (NASDAQ:MIST) Insider Sells $134,576.24 in Stock

Milestone Pharmaceuticals Inc. (NASDAQ:MIST) insider David Bharucha sold 58,007 shares of Milestone Pharmaceuticals stock in a transaction that occurred on Monday, December 15th. The shares were sold at an average price of $2.32, for a total transaction of $134,576.24. Following the sale, the insider owned 91,993 shares in the company, valued at approximately $213,423.76. The trade was a 38.67% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

David Bharucha also recently made the following trade(s):

• On Monday, January 26th, David Bharucha sold 12,245 shares of Milestone Pharmaceuticals stock. The stock was sold at an average price of $1.93, for a total transaction of $23,632.85.

Milestone Pharmaceuticals Stock Performance

Shares of NASDAQ MIST opened at $1.91 on Friday. The company has a market cap of $162.67 million, a P/E ratio of -2.33 and a beta of 0.44. Milestone Pharmaceuticals Inc. has a 52-week low of $0.63 and a 52-week high of $3.06. The company has a debt-to-equity ratio of 2.74, a quick ratio of 8.24 and a current ratio of 8.24. The firm’s fifty day moving average is $2.22 and its two-hundred day moving average is $1.97.

Milestone Pharmaceuticals (NASDAQ:MIST) last issued its quarterly earnings data on Wednesday, November 12th. The company reported ($0.12) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.17) by $0.05. As a group, analysts anticipate that Milestone Pharmaceuticals Inc. will post -0.62 EPS for the current fiscal year.

Hedge Funds Weigh In On Milestone Pharmaceuticals

A number of hedge funds have recently added to or reduced their stakes in MIST. Sapient Capital LLC bought a new stake in shares of Milestone Pharmaceuticals during the third quarter valued at approximately $25,000. Bank of America Corp DE grew its stake in Milestone Pharmaceuticals by 200,550.0% in the third quarter. Bank of America Corp DE now owns 16,052 shares of the company’s stock worth $32,000 after purchasing an additional 16,044 shares in the last quarter. Stephenson & Company Inc. purchased a new position in Milestone Pharmaceuticals during the 3rd quarter worth $40,000. Creative Planning raised its position in Milestone Pharmaceuticals by 74.6% during the 2nd quarter. Creative Planning now owns 23,410 shares of the company’s stock valued at $45,000 after purchasing an additional 10,000 shares in the last quarter. Finally, Bay Rivers Group raised its position in Milestone Pharmaceuticals by 72.9% during the 4th quarter. Bay Rivers Group now owns 28,861 shares of the company’s stock valued at $58,000 after purchasing an additional 12,170 shares in the last quarter. 86.18% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of equities research analysts recently issued reports on the stock. HC Wainwright reaffirmed a “buy” rating and set a $8.00 price target on shares of Milestone Pharmaceuticals in a research note on Tuesday, January 6th. TD Cowen upgraded shares of Milestone Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Monday, December 15th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Milestone Pharmaceuticals in a research report on Monday, December 29th. Wells Fargo & Company boosted their price objective on Milestone Pharmaceuticals from $4.00 to $8.00 and gave the stock an “overweight” rating in a research note on Tuesday, December 16th. Finally, Wall Street Zen cut Milestone Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday, January 10th. One investment analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $8.00.

About Milestone Pharmaceuticals

Milestone Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on developing innovative therapies for respiratory diseases. The company’s research emphasizes both biologic and small-molecule approaches designed to improve mucociliary clearance, reduce airway inflammation and address chronic and refractory cough. Milestone’s pipeline targets key underserved conditions such as cystic fibrosis, primary ciliary dyskinesia and severe asthma.

Milestone’s lead product candidates are delivered through inhalation or systemic administration, reflecting the company’s commitment to optimizing therapeutic delivery directly to the lungs.